Barclays PLC Has $3.80 Million Holdings in Fulgent Genetics, Inc. (NASDAQ:FLGT)

Barclays PLC boosted its holdings in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) by 22.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 174,855 shares of the company’s stock after buying an additional 32,250 shares during the quarter. Barclays PLC’s holdings in Fulgent Genetics were worth $3,800,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Millennium Management LLC increased its holdings in shares of Fulgent Genetics by 34.3% during the 2nd quarter. Millennium Management LLC now owns 958,852 shares of the company’s stock valued at $18,813,000 after acquiring an additional 244,981 shares during the last quarter. State Street Corp boosted its position in Fulgent Genetics by 1.4% during the third quarter. State Street Corp now owns 793,545 shares of the company’s stock worth $17,244,000 after purchasing an additional 10,868 shares during the period. Divisadero Street Capital Management LP grew its holdings in Fulgent Genetics by 46.4% during the second quarter. Divisadero Street Capital Management LP now owns 505,212 shares of the company’s stock valued at $9,912,000 after purchasing an additional 160,212 shares during the last quarter. Point72 Asset Management L.P. bought a new position in shares of Fulgent Genetics in the third quarter valued at approximately $5,854,000. Finally, Invenomic Capital Management LP lifted its stake in shares of Fulgent Genetics by 98.9% in the third quarter. Invenomic Capital Management LP now owns 249,747 shares of the company’s stock worth $5,427,000 after buying an additional 124,185 shares during the last quarter. 48.06% of the stock is currently owned by institutional investors.

Fulgent Genetics Stock Down 2.2 %

Shares of FLGT stock opened at $18.34 on Monday. The stock has a 50 day moving average of $19.45 and a 200-day moving average of $20.92. The firm has a market cap of $560.97 million, a PE ratio of -3.32 and a beta of 1.42. Fulgent Genetics, Inc. has a 12 month low of $16.56 and a 12 month high of $30.68.

Insider Activity at Fulgent Genetics

In related news, CEO Ming Hsieh sold 2,227 shares of Fulgent Genetics stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $18.26, for a total transaction of $40,665.02. Following the sale, the chief executive officer now directly owns 703,711 shares of the company’s stock, valued at $12,849,762.86. This trade represents a 0.32 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 3,413 shares of company stock worth $62,321 in the last ninety days. 31.76% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Piper Sandler lowered their target price on shares of Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating on the stock in a research note on Monday, November 11th. StockNews.com downgraded Fulgent Genetics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 27th.

Fulgent Genetics Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.